This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Tuberculosis
and you are
between 18 and 55
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this study is to evaluate the safety profile of an adjuvanted TB subunit vaccine administered at 0 and 2 months.

Provided treatments

  • Biological: 50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)
  • Biological: 50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)
Tris trial is registered with FDA with number: NCT00929396. The sponsor of the trial is Statens Serum Institut and it is looking for 20 volunteers for the current phase.
Official trial title:
A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)Administered in PPD Positive Volunteers at 0 and 2 Months